

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC,  
Petitioner,

v.

MERCK SHARP & DOHME CORP.,  
Patent Owner.

---

Case No. IPR2020-00040  
U.S. Patent No. 7,326,708

---

**DECLARATION OF ALEXANDER S. ZOLAN IN SUPPORT OF UNOPPOSED  
MOTION FOR PRO HAC VICE ADMISSION PURSUANT TO 37 C.F.R. § 42.10(c)**

Merck Exhibit 2025  
Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.  
IPR2020-00040

I, Alexander S. Zolan, am more than twenty-one years of age, am competent to present this declaration, have personal knowledge of the facts set forth herein, and hereby declare as follows:

1. This declaration is given in support of Patent Owner Merck Sharp & Dohme Corp.'s Motion for *Pro Hac Vice* Admission of Alexander S. Zolan.
2. I am a partner at Williams & Connolly LLP, 725 12th St., NW, Washington, DC 20005. I have more than seven years of litigation experience.
3. I am a member in good standing of the bars of New York and the District of Columbia.
4. I have never been suspended or disbarred from practice before any court or administrative body.
5. No court or administrative body has ever denied my application for admission to practice before it.
6. No court or administrative body has ever imposed sanctions or contempt citations on me.
7. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
8. I understand that I will be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq.
9. Within the last three (3) years, I have applied to appear *pro hac vice* in one (1) other proceeding before the Office. *See Argentum Pharms, LLC v. Alcon Research, LTD.*, IPR2017-01053, Paper 11 (P.T.A.B. Oct. 16, 2017). That application was granted. *Id.* at Paper 15.

Merck Exhibit 2025  
Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.  
IPR2020-00040

10. I am familiar with the subject matter at issue in the present proceeding. This familiarity comes from having:

- a) Reviewed in detail the pleadings submitted by Petitioner in this Case No. IPR2020-00040;
- b) Reviewed in detail the challenged patent, U.S. Patent No. 7,326,708;
- c) Reviewed in detail exhibits relied upon by Petitioner, such as Exhibit 1002 (Declaration of Dr. Mukund Chorghade, Ph.D.);
- d) Engaged in extensive strategic and substantive discussions regarding this proceeding with Stanley E. Fisher, who is the lead counsel for Patent Owner Merck Sharp & Dohme Corp. in this case;
- e) Engaged in the representation of Patent Owner Merck Sharp & Dohme Corp. in this case in related matters in federal district courts, including the assertion of U.S. Patent No. 7,326,708 in *Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc.*, C.A. No. 19-cv-101-IMK (N.D.W.V.) and *In Re: Sitagliptin Patent Litigation*, MDL No. 19-2902-RGA (D. Del.) (consolidated).

11. I have reviewed in detail relevant case law and other legal authority related to the allegations made in the Petition.

\* \* \*

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are

Merck Exhibit 2025  
Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.  
IPR2020-00040

punishable by fine or imprisonment, or both, under Section 1001 of Title 18, United States Code and may jeopardize the validity of any application or any patent issuing thereon.

/Alexander S. Zolan/  
Alexander S. Zolan

Merck Exhibit 2025  
Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.  
IPR2020-00040